达格列净治疗2型糖尿病伴心功能不全效果及对患者心脏功能血小板淋巴细胞比值及血浆hcy水平的影响

doi:10.3969/j.issn.1006-6233.2021.11.027

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1207 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探究达格列净治疗2型糖尿病伴心功能不全效果及对患者心脏功能、血小板淋巴细胞比值(PLR)及血浆同型半胱氨酸(hcy)水平的影响。方法: 选取2019年1月至2020年1月于本院住院及门诊就诊的171例2型糖尿病伴心功能不全患者,按简单随机法分为对照组(n=85)和观察组(n=86),对照组给予常规治疗,观察组在以上基础给予达格列净。比较两组临床疗效、血糖水平[糖化血红蛋白(HbA1c)、空腹血糖(FPG)及餐后2h血糖(2hPG)]、心脏功能[左室射血分数(LVEF)、左室舒张末期内径(LVEDD)及6min步行试验(6MWT)]、PLR和血浆hcy水平及不良反应发生情况。结果: 观察组总有效率为94.19%,明显高于对照组的84.71%(P<0.05);治疗后,与对照组相比,观察组HbA1c、FPG、2hPG水平明显较低(P<0.05),LVEF、6MWT水平明显较高(P<0.05),LVEDD、PLR和血浆hcy水平明显较低(P<0.05);观察组不良反应发生率为10.47%,略高于对照组的5.88%,(P>0.05)。结论: 针对2型糖尿病伴心功能不全患者给予达格列净,具有较好的临床疗效,可明显改善患者的血糖水平和心脏功能,调节PLR和血浆hcy水平,安全性较好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：达格列净, 2型糖尿病, 心功能不全, 心脏功能, 血小板淋巴细胞比值, 血浆hcy

Abstract：Objective: To explore the effect of Dapagliflozin on heart function, platelet lymphocyte ratio (PLR) and plasma homocysteine (hcy) in patients with type 2 diabetes mellitus. Methods: 171 patients with type 2 diabetes mellitus complicated with cardiac insufficiency in our hospital from January 2019 to January 2020 were randomly divided into comparison group (n=85) and observation group (n=86). Clinical efficacy, blood glucose level [glycosylated hemoglobin (HbA1c), fasting blood glucose (FPG) and 2h postprandial blood glucose (2hPG)], cardiac function [left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD) and 6 min walking test (6MWT)], PLR, plasma hcy level and adverse reactions were compared between the two groups. Results: The total effective rate of the observation group was 94.19%, which was significantly higher than that of the control group (84.71%) (P<0.05); after treatment, compared with the control group, the observation group had significantly lower levels of HbA1c, FPG and 2hPG (P<0.05), LVEF, 6MWT levels were significantly higher (P<0.05), LVEDD, PLR, and plasma hcy levels were significantly lower (P<0.05); the incidence of adverse reactions in the observation group was 10.47%, slightly higher than 5.88% in the control group. (P>0.05). Conclusion: Dapagliflozin for patients with type 2 diabetes complicated with cardiac insufficiency has a good clinical effect, which can obviously improve the blood glucose level and cardiac function of patients, regulate PLR and plasma hcy levels, and has good safety.

Key words： Dapagliflozin Type 2 diabetes Cardiac insufficiency Heart function Platelet lymphocyte ratio Plasma hcy

基金资助:安徽省自然科学研究项目,(编号:12925K2017B06)

引用本文:

王卓群, 申金付, 牛敏, 马兴坡, 李娟. 达格列净治疗2型糖尿病伴心功能不全效果及对患者心脏功能血小板淋巴细胞比值及血浆hcy水平的影响[J]. 河北医学, 2021, 27(11): 1897-1901.
WANG Zhuoqun, SHEN Jinfu, NIU Min, et al. The Effect of Dapagliflozin on Type 2 Diabetes Mellitus with Cardiac Insufficiency and Its Influence on Cardiac Function Platelet Lymphocyte Ratio and Plasma Hcy Level. HeBei Med, 2021, 27(11): 1897-1901.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.11.027 或 http://www.hbyxzzs.cn/CN/Y2021/V27/I11/1897

[1] 李玉,段敬柱.心理应激对冠心病合并2型糖尿病患者PCI术后糖代谢、胰岛素抵抗及炎症介质水平的影响[J].中国健康心理学杂志,2019,27(1):89~92.
[2] Diabetic Cardiomyopathy:Definition,diagnosis,and therapeutic implications[J].Heart fail clin,2019,15(3):341~347.
[3] 胡姗姗,肖莉,胡菁,等.阿托伐他汀联合苯那普利治疗冠心病合并2型糖尿病心功能不全者56例疗效观察[J].中国临床医生杂志,2018,46(11):1296~1299.
[4] Dawwas G K,Smith S M,Haesuk P.Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes[J].Diabetes Obes Metab,2019,9(1):28~36.
[5] 贾伟平,陆菊明.中国2型糖尿病防治指南(2017年版)[J].中华医学会糖尿病学分会,2018,10(1):2,67.
[6] 林少华,陈美卿.盐酸曲美他嗪治疗2型糖尿病合并慢性心功能不全患者的临床效果分析[J].中国当代医药,2018,25(23):158~161.
[7] 余凤,夏漫,刘丹,等.老年2型糖尿病患者HbA1c与CYFRA21-1、CA199水平的相关性分析[J].糖尿病新世界,2021,24(3):7~9.
[8] 郭丽婷,葛焕琦,高志红.达格列净对使用胰岛素联合利拉鲁肽或沙格列汀治疗不理想的2型糖尿病患者影响的研究[J].中国糖尿病杂志,2019,27(5):343~346.
[9] 游月婷,汪汉,徐俊波.达格列净在心力衰竭治疗中的研究进展[J].心血管病学进展,2020,41(8):830~833.
[10] 史晓荻,魏志杰.SGLT-2抑制剂联合常规降糖治疗对2型糖尿病患者血管内皮功能的影响[J].安徽医学,2020,41(1):42~46.
[11] 王彦春,张俊峰,周星璇.动态监测外周血NLR和PLR预测STEMI合并2型糖尿病患者PCI术后短期预后的价值[J].广东医学,2019,40(4):142~146.
[12] 杨震,董健,张军涛,等.达格列净在2型糖尿病合并心功能不全患者中应用的临床评价分析[J].重庆医学,2019,48(16):2861~2863.